Hemorrhage promotes chronic adverse remodeling in acute myocardial infarction: a T1 , T2 and BOLD study

Stephania Assimopoulos1, Nancy Shie2, Venkat Ramanan2

  • 1Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.

NMR in Biomedicine
|September 3, 2020
PubMed

Insights

Myocardial hemorrhage worsens heart attack outcomes by increasing damage, inflammation, and adverse remodeling. Understanding these effects may lead to new treatments for heart failure.

Area of Science:

  • Cardiovascular Research
  • Pathophysiology
  • Medical Imaging

Background:

  • Hemorrhage is an emerging predictor of poor outcomes after acute myocardial infarction.
  • The underlying mechanisms linking hemorrhage to adverse cardiac events remain unclear.

Purpose of the Study:

  • To investigate the chronic effects of myocardial hemorrhage on cardiac remodeling, inflammation, and vasodilator function.
  • To elucidate the downstream consequences of hemorrhage beyond the initial ischemic insult using an experimental porcine model.

Main Methods:

  • Myocardial hemorrhage was induced via intracoronary collagenase injection in a porcine model.
  • Animals underwent coronary occlusion/reperfusion with or without hemorrhage, followed by MRI up to 4 weeks.
  • Cardiac function, edema, hemorrhage, vasodilator function, infarct size, and microvascular obstruction were assessed.

Main Results:

  • Hemorrhage significantly increased infarct size, microvascular obstruction, and adverse cardiac remodeling compared to ischemia alone.
  • Hemorrhage led to compromised cardiac function, enlarged ventricular volume, and remote myocardial alterations.
  • Edema and matrix expansion were greatest in the infarct zone of the hemorrhage groups.

Conclusions:

  • Myocardial hemorrhage at reperfusion exacerbates myocardial damage and promotes chronic adverse remodeling.
  • Hemorrhage induces inflammation and remote myocardial changes, contributing to heart failure progression.
  • Understanding hemorrhage's impact is crucial for developing targeted therapies for high-risk cardiac patients.